Wegovy (semaglutide 2.4 mg) is a once-weekly subcutaneous injection that has become one of the most clinically significant weight management medications in modern medicine. Developed by Novo Nordisk and approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021, Wegovy represents the first GLP-1 receptor agonist approved specifically for chronic weight management in nearly a decade. Its approval was backed by the landmark STEP clinical trial program, which demonstrated unprecedented weight loss outcomes in a non-surgical setting.
What Is Semaglutide?
Semaglutide is a human GLP-1 analogue — a synthetic version of the naturally occurring incretin hormone glucagon-like peptide-1. It shares approximately 94% structural homology with native human GLP-1 but incorporates two key chemical modifications: a single amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid), which confers resistance to DPP-4 degradation, and the attachment of a C-18 fatty diacid chain via a linker that allows reversible albumin binding. This albumin binding dramatically extends the drug’s half-life to approximately 165–184 hours (approximately 7 days), enabling convenient once-weekly dosing.
Critically, the dose used in Wegovy (2.4 mg weekly) is higher than the dose used in Ozempic (0.5–2 mg weekly), which is the same semaglutide molecule approved for type 2 diabetes management. The higher dose produces greater central appetite suppression and correspondingly greater weight loss, though it is not specifically indicated as a diabetes treatment.
FDA Approval and Indications
The FDA approved Wegovy for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who meet one of the following criteria:
- BMI ≥ 30 kg/m² (obesity), regardless of the presence of comorbidities
- BMI ≥ 27 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
In December 2023, the FDA expanded Wegovy’s indication to include reduction of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight — based on the results of the SELECT trial, which demonstrated a 20% relative risk reduction in major adverse cardiovascular events.
How Wegovy Produces Weight Loss
Semaglutide at the 2.4 mg dose activates GLP-1 receptors throughout the body with high potency and sustained duration. The primary mechanisms contributing to weight loss include:
- Hypothalamic appetite suppression: GLP-1 receptors in the arcuate nucleus, paraventricular nucleus, and nucleus tractus solitarius reduce appetite-stimulating neuropeptides (neuropeptide Y, AgRP) and increase satiety signals (POMC/CART neurons).
- Delayed gastric emptying: Slowed gastric transit extends postprandial fullness and reduces the speed of glucose absorption, flattening postprandial glucose peaks and sustaining satiety signals.
- Reward pathway modulation: Evidence from functional neuroimaging suggests semaglutide reduces the brain’s hedonic response to food cues, diminishing food cravings particularly for high-fat and high-sugar items.
- Reduced energy intake: Clinical studies consistently show that patients on semaglutide 2.4 mg spontaneously reduce caloric intake by approximately 30% compared to placebo, even without formal dietary counseling.
The STEP Clinical Trial Program: What the Evidence Shows
Wegovy’s approval was supported by the Semaglutide Treatment Effect in People with Obesity (STEP) program, a series of Phase 3 randomized controlled trials:
- STEP 1 (Wilding et al., NEJM 2021): 1,961 adults without diabetes. After 68 weeks, participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight (approximately 15.3 kg) versus 2.4% in the placebo group. Approximately 69% of participants achieved ≥10% weight loss, and 50% achieved ≥15% weight loss on semaglutide.
- STEP 2: Adults with type 2 diabetes. Mean weight loss of 9.6% versus 3.4% placebo; also demonstrated significant HbA1c reduction.
- STEP 3: Combined semaglutide with intensive behavioral therapy. Mean weight loss of 16% over 68 weeks.
- STEP 4: Withdrawal trial demonstrating that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight by week 68, underscoring the need for long-term treatment.
- STEP 5: Two-year data showing sustained weight loss of approximately 15.2% at 104 weeks.
💡 💡 Clinical Pearl
The STEP 4 withdrawal trial is one of the most clinically important findings in GLP-1 RA research. When patients who had achieved significant weight loss discontinued semaglutide, they regained approximately 6.9% of their body weight within 12 months compared to continued treatment. This confirms that obesity is a chronic disease requiring long-term pharmacotherapy — analogous to how antihypertensives must be continued indefinitely to maintain blood pressure control. Discontinuation decisions should be made with the patient’s full understanding of this rebound risk.
Dosing Schedule: The 16-Week Titration
Wegovy is initiated at a low dose and gradually increased over 16 weeks to minimize gastrointestinal side effects. The approved titration schedule is:
- Weeks 1–4: 0.25 mg once weekly (initiation dose; not a therapeutic dose for weight loss)
- Weeks 5–8: 0.5 mg once weekly
- Weeks 9–12: 1.0 mg once weekly
- Weeks 13–16: 1.7 mg once weekly
- Week 17 onwards: 2.4 mg once weekly (maintenance dose)
If a patient does not tolerate a dose escalation step due to gastrointestinal side effects (nausea, vomiting, diarrhea), the prescriber may delay dose escalation by 4 additional weeks at the previous dose. For details on managing titration, see Step-by-Step Dosing and Titration Guide for GLP-1 RA Medications.
Common Side Effects and Management
The most commonly reported adverse effects of Wegovy are gastrointestinal in nature and are related to the drug’s effect on gastric motility:
- Nausea (44% of patients vs. 16% placebo) — typically most pronounced in the first weeks of each dose escalation, and often improves with time
- Diarrhea (30%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
Serious but rare adverse events include pancreatitis, gallbladder disease (cholelithiasis), and — based on animal data — a theoretical risk of medullary thyroid carcinoma. Wegovy carries a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
For complete storage and handling instructions for the Wegovy pen, see Proper Storage and Handling of GLP-1 RA Pens.
💡 Frequently Asked Questions (FAQ)
Q1: How long does it take to see weight loss results with Wegovy?
A1: Most patients begin to notice appetite reduction within the first few weeks, but meaningful weight loss (5% or more of body weight) is typically observed by weeks 12–20. Maximum weight loss in clinical trials was generally observed around weeks 60–68. The therapeutic dose of 2.4 mg is not reached until week 17, so patients should not judge effectiveness too early.
Q2: What happens if I miss a dose of Wegovy?
A2: If fewer than 5 days have passed since the missed dose, inject it as soon as you remember and then resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose and resume on your next regularly scheduled injection day. Never inject two doses within 2 days of each other.
Q3: Is Wegovy the same as Ozempic?
A3: Both contain semaglutide, but they are not the same product. Ozempic is approved at doses of 0.5–2 mg weekly for type 2 diabetes. Wegovy is approved at 2.4 mg weekly for chronic weight management. They have different pen devices, different dose increments, and different FDA indications. Using Ozempic off-label for weight loss has raised supply concerns for patients with diabetes who need it.
📚 References & Sources
- Wilding, J.P.H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
- FDA. (2021). Prescribing Information: Wegovy (semaglutide) injection 2.4 mg. U.S. Food and Drug Administration.
- American Diabetes Association. (2024). Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care, 47(Suppl.1).